Nano cap Opexa Therapeutics (OPXA +47.7%) jumps on more than triple normal volume. Shares are up 160% since bottoming at $0.50 on November 9 after the Tcelna flop in a multiple sclerosis study.
No particular news accounts for the action, but the company stated in a November 14 press release that its quick assets will only be sufficient to fund operations into Q1. An equity offering could be announced any time.
Subscribe for full text news in your inbox